Glenmark Life Sciences Ltd. IPO
IPO Timeline
Category-wise Subscription
| Category | Sub (x) | Offered | Bid For | Amt (Cr)* |
|---|---|---|---|---|
| QIB | — | 10,511,110 (50%) | — | ₹75,680 Cr |
| NII (HNI) | — | 3,153,334 (15%) | — | ₹22,704 Cr |
| Retail | — | 7,357,778 (35%) | — | ₹52,976 Cr |
| Σ Total | — | 21,022,222 (100%) | — | ₹1,513,600 Cr |
Only available investor categories are shown. Amount is auto-calculated when shares offered and issue price are available.
Issue Details
Minimum Investment (Lot-wise)
| Category | Lots | Shares | Amount (₹) |
|---|---|---|---|
| Retail (Min) | 1 | 20 | ₹14,400 |
| Retail (Max) | 13 | 260 | ₹187,200 |
| S-HNI (Min) | 14 | 280 | ₹201,600 |
| B-HNI (Min) | 67 | 1,340 | ₹964,800 |
Financial Statements Amount in Crore
| Metric | 31-Mar-21 | 31-Mar-20 | 31-Mar-19 |
|---|---|---|---|
| Revenue | 1,886 | 1,549 | 887 |
| Profit After Tax | 352 | 313 | 196 |
| Total Assets | 1,997 | 1,726 | 1,475 |
Valuation & Key Ratios
Grey Market Premium (GMP)
GMP is an unofficial grey market indicator and does not guarantee actual listing price. Invest at your own risk.
Objects of the Issue
- 1 Payment of outstanding purchase consideration to the Promoter for thespin-off of the API business from the Promoter into our Companypursuant to the Business Purchase Agreementdated October 9, 2018 – 800.00
- 2 Funding the capital expenditure requirements – 152.76
- 3 General corporate purposes – 57.68
Company Overview
Incorporated in 2011, Glenmark Life Sciences is the leading manufacturer of Active Pharmaceutical Ingredients (APIs). The company develops, manufactures, and supplies high-quality APIs for cardiovascular disease (CVS), central nervous system disease (CNS), pain management, and diabetes, gastrointestinal disorders, anti-infectives, and other therapeutic areas. It further operates in Contract Development and manufacturing operations (CDMO) to offer services to specialty Pharmaceutical companies.
Its products are being sold in India and also expoted to multiple countries i.e. Europe, North America, Latin America, Japan, etc. Currently, it has 4 manufacturing facilities at Ankleshwar and Dahej in Gujarat and Mohol and Kurkumbh in Maharashtra State with an aggregate annual installed capacity of 725.8 KL as of December 31, 2020.
Competitive strengths
- Leading manufacturer of selected specialized APIs for chronic therapeutic areas like CVS, CNS, diabetes, and pain management.
- Export products in Europe, Latin America, North America, Japan, and the rest of the world.
- Strong relationship with leading global generic companies.
- Proven track record of strong financial performance.
- High-quality product manufacturing with R&D infrastructure.